The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Alex A. Adjei

Mayo Clinic and Foundation

Division of Medical Oncology

Rochester

MN 55905

USA

[email]@mayo.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Mayo Clinic and Foundation, Division of Medical Oncology, Rochester, MN 55905, USA. 1999 - 2006
  • Department of Oncology, Mayo Clinic and Foundation, Rochester, USA. 2000 - 2005
  • Division of Medical Oncology, Mayo Clinic, 200 First Street S.W., Rochester, USA. 2002 - 2005

References

  1. Clinical studies of pemetrexed and gemcitabine combinations. Adjei, A.A. Ann. Oncol. (2006) [Pubmed]
  2. Novel combinations based on epidermal growth factor receptor inhibition. Adjei, A.A. Clin. Cancer Res. (2006) [Pubmed]
  3. Intracellular signal transduction pathway proteins as targets for cancer therapy. Adjei, A.A., Hidalgo, M. J. Clin. Oncol. (2005) [Pubmed]
  4. Farnesyltransferase inhibitors. Adjei, A.A. Cancer. Chemother. Biol. Response. Modif (2005) [Pubmed]
  5. Targeting multiple signal transduction pathways in lung cancer. Adjei, A.A. Clin. Lung. Cancer (2005) [Pubmed]
  6. Sequencing bortezomib with chemotherapy and targeted agents. Adjei, A.A. Clin. Lung. Cancer (2005) [Pubmed]
  7. The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy. Adjei, A.A. Clin. Lung. Cancer (2005) [Pubmed]
  8. Pharmacology and mechanism of action of pemetrexed. Adjei, A.A. Clin. Lung. Cancer (2004) [Pubmed]
  9. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Adjei, A.A. Clin. Cancer Res. (2004) [Pubmed]
  10. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Adjei, A.A., Dy, G.K., Erlichman, C., Reid, J.M., Sloan, J.A., Pitot, H.C., Alberts, S.R., Goldberg, R.M., Hanson, L.J., Atherton, P.J., Watanabe, T., Geary, R.S., Holmlund, J., Dorr, F.A. Clin. Cancer Res. (2003) [Pubmed]
  11. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. Adjei, A.A., Mauer, A., Bruzek, L., Marks, R.S., Hillman, S., Geyer, S., Hanson, L.J., Wright, J.J., Erlichman, C., Kaufmann, S.H., Vokes, E.E. J. Clin. Oncol. (2003) [Pubmed]
  12. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Adjei, A.A. Expert. Rev. Anticancer. Ther (2003) [Pubmed]
  13. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Adjei, A.A., Croghan, G.A., Erlichman, C., Marks, R.S., Reid, J.M., Sloan, J.A., Pitot, H.C., Alberts, S.R., Goldberg, R.M., Hanson, L.J., Bruzek, L.M., Atherton, P., Thibault, A., Palmer, P.A., Kaufmann, S.H. Clin. Cancer Res. (2003) [Pubmed]
  14. An overview of farnesyltransferase inhibitors and their role in lung cancer therapy. Adjei, A.A. Lung. Cancer (2003) [Pubmed]
  15. Novel anticancer agents in clinical development. Adjei, A.A., Rowinsky, E.K. Cancer Biol. Ther. (2003) [Pubmed]
  16. Current data with pemetrexed (Alimta) in non-small-cell lung cancer. Adjei, A.A. Clin. Lung. Cancer (2003) [Pubmed]
  17. Farnesyltransferase inhibitors. Adjei, A.A. Cancer. Chemother. Biol. Response. Modif (2003) [Pubmed]
  18. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. Adjei, A.A., Reid, J.M., Diasio, R.B., Sloan, J.A., Smith, D.A., Rubin, J., Pitot, H.C., Alberts, S.R., Goldberg, R.M., Hanson, L.J., Atherton, P., Ames, M.M., Erlichman, C. J. Clin. Oncol. (2002) [Pubmed]
  19. Pemetrexed (Alimta) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes. Adjei, A.A. Clin. Breast Cancer (2002) [Pubmed]
  20. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Adjei, A.A., Reid, J.M., Erlichman, C., Sloan, J.A., Pitot, H.C., Alberts, S.R., Goldberg, R.M., Hanson, L.J., Ruben, S., Boemer, S.A., Atherton, P., Ames, M.M., Kaufmann, S.H. Invest. New. Drugs (2002) [Pubmed]
  21. Farnesyltransferase inhibitors in breast cancer therapy. Dy, G.K., Adjei, A.A. Cancer Invest. (2002) [Pubmed]
  22. Farnesyltransferase inhibitors. Adjei, A.A. Cancer. Chemother. Biol. Response. Modif (2002) [Pubmed]
  23. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Adjei, A.A., Davis, J.N., Bruzek, L.M., Erlichman, C., Kaufmann, S.H. Clin. Cancer Res. (2001) [Pubmed]
  24. Ras signaling pathway proteins as therapeutic targets. Adjei, A.A. Curr. Pharm. Des. (2001) [Pubmed]
  25. Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Adjei, A.A. Lung. Cancer (2001) [Pubmed]
  26. Receptor tyrosine kinase inhibitors. Haluska, P., Adjei, A.A. Curr. Opin. Investig. Drugs (2001) [Pubmed]
  27. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. Adjei, A.A., Klein, C.E., Kastrissios, H., Goldberg, R.M., Alberts, S.R., Pitot, H.C., Sloan, J.A., Reid, J.M., Hanson, L.J., Atherton, P., Rubin, J., Erlichman, C. J. Clin. Oncol. (2000) [Pubmed]
  28. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. Adjei, A.A., Erlichman, C., Sloan, J.A., Reid, J.M., Pitot, H.C., Goldberg, R.M., Peethambaram, P., Atherton, P., Hanson, L.J., Alberts, S.R., Jett, J. J. Clin. Oncol. (2000) [Pubmed]
  29. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Adjei, A.A., Erlichman, C., Davis, J.N., Cutler, D.L., Sloan, J.A., Marks, R.S., Hanson, L.J., Svingen, P.A., Atherton, P., Bishop, W.R., Kirschmeier, P., Kaufmann, S.H. Cancer Res. (2000) [Pubmed]
  30. Comparison of potential markers of farnesyltransferase inhibition. Adjei, A.A., Davis, J.N., Erlichman, C., Svingen, P.A., Kaufmann, S.H. Clin. Cancer Res. (2000) [Pubmed]
  31. Management of small cell cancer of the lung. Adjei, A.A. Curr. Opin. Pulm. Med (2000) [Pubmed]
  32. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Adjei, A.A. Ann. Oncol. (2000) [Pubmed]
  33. Current status of pyrazoloacridine as an anticancer agent. Adjei, A.A. Invest. New. Drugs (1999) [Pubmed]
 
WikiGenes - Universities